Zobrazeno 1 - 10
of 251
pro vyhledávání: '"MARKUS JOERGER"'
Autor:
Francis Williams Ojara, Andrea Henrich, Nicolas Frances, Yomna M. Nassar, Wilhelm Huisinga, Niklas Hartung, Kimberly Geiger, Stefan Holdenrieder, Markus Joerger, Charlotte Kloft
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 11, Pp 1714-1725 (2023)
Abstract Paclitaxel/platinum chemotherapy, the backbone of standard first‐line treatment of advanced non‐small cell lung cancer (NSCLC), exhibits high interpatient variability in treatment response and high toxicity burden. Baseline blood biomark
Externí odkaz:
https://doaj.org/article/a66563bd6bf14dcaa78e5deef69f42e4
Autor:
Maximilian Boesch, Florent Baty, Frank Rassouli, Tobias Kowatsch, Markus Joerger, Martin Früh, Martin H. Brutsche
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTThe traditional picture of cancer patients as weak individuals requiring maximum rest and protection is beginning to dissolve. Too much focus on the medical side and one’s own vulnerability and mortality might be counterproductive and not d
Externí odkaz:
https://doaj.org/article/c161ba4d3fa0448cb631e7f204bfecca
Autor:
Thomas Yau, Ignacio Garrido-Laguna, Pierre-Eric Juif, Markus Joerger, Anna Spreafico, Todd M Bauer, Chia-Chi Lin, Armando Santoro, Richard Greil, Helen Evans, Marc Pelletier, Toshikiko Doi, Maria-Elisabeth Goebeler, Viviana Cremasco, Marie Luise Hütter-Krönke, Antonella Perotti, Darlene Lu, Louise Barys, Claire Fabre
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background NIS793 is a human IgG2 monoclonal antibody that binds to transforming growth factor beta (TGF-β). This first-in-human study investigated NIS793 plus spartalizumab treatment in patients with advanced solid tumors.Methods Patients received
Externí odkaz:
https://doaj.org/article/e339d08408a2485f90c3737b27e2f7e9
Autor:
Markus Joerger, Emiliano Calvo, Heinz Läubli, Juanita Lopez, Elena Garralda, Dagmar Hess, Elena Corral de la Fuente, Christoph Bucher, Guzman Alonso, Sangeeta Jethwa, David König, Vicky Sanchez Perez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background ANV419 is a stable antibody–cytokine fusion protein consisting of interleukin-2 (IL-2) fused to an anti-IL-2 monoclonal antibody that sterically hinders binding of IL-2 to the α subunit of its receptor but has selective affinity for the
Externí odkaz:
https://doaj.org/article/c922b1eb4e8b44009c63d9e58c5680a1
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 3, Iss 1, Pp 27-36 (2022)
Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characteristics. ADCs represent a class of therapeutics that com
Externí odkaz:
https://doaj.org/article/555f1ecf6e8244a0b551fa828bf51f4f
Autor:
David Blum, Caroline Hertler, Rolf Oberholzer, Susanne deWolf‐Linder, Markus Joerger, Christoph Driessen, Florian Strasser
Publikováno v:
JCSM Rapid Communications, Vol 5, Iss 1, Pp 68-76 (2022)
Abstract Background Cancer cachexia (CC) impacts quality of life, physical function, anticancer treatment response, and survival. Inflammation is a prominent pathomechanism of CC. This small‐scale study sets out to investigate the immunomodulatory
Externí odkaz:
https://doaj.org/article/5fa6f6eb82c44c82a47ca0e7aebb1323
Autor:
Stefan Diem, Markus Joerger, Fiamma Berner, Lukas Flatz, Niklas Klümper, Manuel Ritter, Michael Hölzel, Jörg Ellinger, Peter Brossart, Annkristin Heine, Jonas Saal, Christa Lichtensteiger, Nina Wyss, Franz Georg Bauernfeind, Sabine Schmid, Martin Frueh, Tobias Bald
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Biomarkers for predicting response to anti-programmed death-1 (PD-1) immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) remain in demand. Since anti-tumor immune activation is a process, early dynamic changes of the acute-phase re
Externí odkaz:
https://doaj.org/article/a419b057817a4ab6b93221e6e2d22e8a
Autor:
Zuzana Zděblová Čermáková, Pavel Hurník, David Konvalinka, Jan Štembírek, Tereza Paračková, Kamila Resová, Jakub Cvek, Tomáš Blažek, Lukáš Knybel, Martin Formánek, Mariam Gachechiladze, Markus Joerger, Alex Soltermann, Jozef Škarda, Oldřich Motyka, Jana Janoutová
Publikováno v:
Medicina, Vol 59, Iss 2, p 361 (2023)
Introduction: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to pred
Externí odkaz:
https://doaj.org/article/dc3fbdc18cc242049c3c14b69da5670d
Autor:
Bart A.W. Jacobs, Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels deVries, Didier Meulendijks, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 12, Pp 940-950 (2019)
Capecitabine is an oral prodrug of the anticancer drug 5‐fluorouracil (5‐FU). The primary aim of this study was to develop a pharmacokinetic model for capecitabine and its metabolites, 5′‐deoxy‐5‐fluorocytidine (dFCR), 5′‐deoxy‐5‐
Externí odkaz:
https://doaj.org/article/8300a5fe4be74766ad22f7c77488aab7
Autor:
Daan P. Hurkmans, Edwin A. Basak, Tanja van Dijk, Darlene Mercieca, Marco W. J. Schreurs, Annemarie J. M. Wijkhuijs, Sander Bins, Esther Oomen-de Hoop, Reno Debets, Markus Joerger, Arlette Odink, Astrid A. M. van der Veldt, Cor H. van der Leest, Joachim G. J. V. Aerts, Ron H. J. Mathijssen, Stijn L. W. Koolen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may argue against the curren
Externí odkaz:
https://doaj.org/article/f8d983aed7774b85a3a382836c2bce1a